Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clearmind Medicine Inc. (CMND : NSDQ)

• Company Description    Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Clearmind Medicine Inc. is based in VANCOUVER. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.98 Daily Weekly Monthly 20 Day Moving Average: 2,224,548 shares Shares Outstanding: 4.27 (millions) Market Capitalization: $4.18 (millions) Beta: 0.93 52 Week High: $2.30 52 Week Low: $0.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.45% 10.16% 12 Week -12.50% -26.40% Year To Date -28.99% -33.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101-1220 WEST 6TH AVENUE - VANCOUVER,A1 V6H1A5 CAN ph: - fax: - invest@clearmindmedicine.com http://www.clearmindmedicine.com

• General Corporate Information    Officers Adi Zuloff-Shani - Chief Executive Officer Amitay Weiss - Chairman of the Board of Director Alan Rootenberg - Chief Financial Officer Yehonatan Shachar - Director Oz Adler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 185053402 SIC: 2834 Fiscal Year Fiscal Year End: October Last Reported Quarter: 04/01/25 Next Expected EPS Date: 09/15/25 Share - Related Items Shares Outstanding: 4.27 Most Recent Split Date: 11.00 (0.03:1) Beta: 0.93 Market Capitalization: $4.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/15/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.82 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/25 - -164.79 01/31/25 - -140.87 10/31/24 - -129.21 ROA 04/30/25 - -71.12 01/31/25 - -64.28 10/31/24 - -61.15 Current Ratio 04/30/25 - 1.74 01/31/25 - 1.72 10/31/24 - 1.72 Quick Ratio 04/30/25 - 1.74 01/31/25 - 1.72 10/31/24 - 1.72 Operating Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Net Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Pre-Tax Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Book Value 04/30/25 - 0.54 01/31/25 - 0.67 10/31/24 - 0.73 Inventory Turnover 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - 0.00 01/31/25 - 0.00 10/31/24 - 0.01 Debt-to-Capital 04/30/25 - 0.00 01/31/25 - 0.24 10/31/24 - 0.53

Powered by Zacks Investment Research ©